



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Utregrlutide

Item No. 41275

CAS Registry No.: 2460862-12-6

Formal Name: L-histidyl-2-methylalanyl-L- α -glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L- α -glutamylglycyl-L-glutamyl-L-alanyl-L-alanyl-N6-[N-(17-carboxy-1-oxoheptadecyl)-L- γ -glutamyl-2-methylalanyl-2-[2-(2-aminoethoxy)ethoxy]acetyl]-L-lysyl-L- α -glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycyl-L-leucine

Synonym: GL0034

MF: $C_{191}H_{298}N_{46}O_{58}$


FW: 4,166.7

Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Utregrlutide is supplied as a solid. A stock solution may be made by dissolving the utregrlutide in the solvent of choice, which should be purged with an inert gas. Utregrlutide is sparingly soluble (1-10 mg/ml) in DMSO.

Description

Utregrlutide is a G protein-biased peptide agonist of glucagon-like peptide 1 receptor (GLP-1R).¹ It selectively induces cAMP accumulation in HEK293 cells expressing human GLP-1R over β -arrestin recruitment in CHO-K1 cells expressing human GLP-1R (EC_{50} s = 0.63 and 79 nM, respectively). Utregrlutide induces insulin secretion in INS-1 832/3 rat insulinoma cells (EC_{50} = 6.3 nM). *In vivo*, utregrlutide (1.5-6 nmol/kg) reduces food intake and body weight, increases plasma insulin levels, and decreases plasma glucose, hemoglobin A1c (HbA1c), glucagon, and triglyceride levels in diabetic *db/db* mice.

Reference

1. Jones, B., Burade, V., Akalestou, E., *et al.* In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist. *Diabetes Obes. Metab.* **24**(11), 2090-2101 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/16/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM